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SUPPLEMENTAL FIGURE LEGENDS 
Supplemental Fig. S1: Analysis of VCP complexes by SEC-mass spectrometry. A, Time 
course of efficiency of VCP knockdown induced by doxycycline (1µg/ml) using HEK293 cell 
line that has a stably integrated, doxycycline-inducible VCP shRNA (DTC204). At the indicated 
time after transfection, cell lysate was prepared and evaluated by SDS-PAGE and Western 
blotting with anti-VCP. The 5 day point was chosen as the condition for all MS experiments, 
since on day 6 a large amount of cell death occurred. B, Violin plots showing the distribution of 
coefficients of variation (n=3) of apex measurements for proteins in each sample. C, Number of 
proteins quantified in each experiment (mean ± SEM, n=3). D, Total abundance change (defined 
as [LFQintensity]treated divided by [LFQintensity]control) for all detected proteins in response to 
VCP knockdown (left panel) or NMS873 treatment (right panel). E, DAVID gene ontology 
keywords for proteins whose mean apex position was increased or decreased by > 2.5 fractions 
upon NMS873 treatment or VCP knockdown. F, Proteins from Fig. 1B with a shift in mean apex 
position of >2.5 fractions, along with a >4 fold increase or decrease in abundance following VCP 
knockdown. PTPN9 (marked with **) is the only protein that met these criteria in both the VCP 
knockdown and NMS873 (panel G) treatment groups. Proteins in red have been reported either 
in BioGRID or in the published literature to bind and/or interact with VCP in some manner. G, 
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Same as panel E, except for the experiment in Fig. 1C in which cells were treated with 10 µM 
NM873 for 6h. 
 
Supplemental Fig. S2: Fractionation of VCP adaptors by SEC. SEC fractionation behavior of 
different classes of VCP adaptors upon perturbation of VCP activity by NMS873 or shRNA-
mediated depletion. A, Class I adaptors co-fractionated with VCP. B, Class II adaptors were 
constitutively assembled in complexes of higher MW than the VCP peak. C, Class III adaptors 
fractionated at MWs lower than VCP and were not affected by either chemical inhibition or 
depletion of VCP. D, The relative LFQ intensities of VCP and adaptors in SEC fractions from 
HEK293 cells (bars represent standard error of the mean, n=3). E, HEK293 lysate from untreated 
cells was chromatographed on a Superose 6 column, and 1 mL fractions were analyzed via 
western blot.  F, In silico-generated SEC chromatograms of representative VCP adaptors in the 
Kirkwood et. al. dataset.  
 
Supplemental Fig. S3: Control experiments for VCP immunoprecipitation. A, Western 
blotting shows the expression of endogenous VCP bearing an N-terminal FLAG tag in HEK293 
cells. Lysates of HEK293
FLAGVCP
 cells were incubated with anti-VCP or anti-FLAG antibody. 
The input, flow through (FT) and bound fractions were separated by SDS-PAGE and blotted 
with anti-VCP or anti-FLAG antibody. Note that the FLAG tag did not cause a perceptible shift 
in the mobility of VCP. WB, Western blot. B, VCP was recovered in IPs as short as 6 min. The 
time indicated above each lane is the duration of the incubation with antibody prior to adding 
protein A/G beads for an additional 5 min to capture immune complexes. As the IP time 
increased, the amount of VCP detected by Western blot decreased in the flow through and 
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increased in the elution. C, Label-free quantification of VCP recovery in IPs of varying duration 
for the experiments in Fig. 3A and Fig. 3B. D, Venn diagram shows the overlap in protein 
identifications comparing FLAG IP from HEK293
FLAGVCP
 cells with IP of untagged endogenous 
VCP from wild type HEK293 cells. n=1 E, Enrichment of VCP adaptors in VCP pull-downs. 
Two experiments were conducted in parallel. In the first experiment (black bars), 
HEK293
FLAGVCP
 and HEK293 cells were grown in medium containing ‘heavy’ or ‘light’ lysine 
plus arginine, respectively. Cell lysates from both cultures were individually subjected to IP with 
anti-FLAG and following the IP step the samples were mixed and analyzed by mass 
spectrometry. In the second experiment (gray bars), Lysate from the ‘heavy’ HEK293 cells was 
subjected to IP with anti-VCP whereas lysate from the ‘light’ HEK293 cells was subjected to 
mock IP (no antibody was present before protein A/G beads added for capture). Following the IP 
step the samples were mixed and analyzed by mass spectrometry. The H/L ratios for known 
VCP-interacting proteins are shown. n=1. 
 
Supplemental Fig. S4: Effect of ND1L ‘sponge’ on recovery of VCP binding proteins 
during immunoprecipitation. Titration of increasing amounts of ‘light’ ND1L into ‘heavy’ cell 
lysate progressively reduced the number of proteins recovered by IP with a VCP antibody that 
does not bind ND1L.  
 
Supplemental Fig. S5: Crosslinked VCP complex can be purified by immunoprecipitation. 
When immunoprecipitated with anti-VCP for 2 hours, most of the cross-linked VCP was 
recovered in the bound fraction. VCP cross-links were largely resolved upon treating the bound 
fraction with the reducing agent DTT. 
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Supplemental Fig. S6: Chemical inhibition of VCP modulates its repertoire of associated 
adaptor proteins in HEK293 cells and BJ fibroblasts. A, Label swap SILAC experiments 
were performed in which cells were either mock-treated or supplemented with 10 µM NMS873 
for 6 hours. Cells were treated with 800 µM DSP for 30 minutes prior to cell lysis, mixing of cell 
lysates, IP with anti-VCP, and mass spectrometry analysis. The ratios for each protein identified 
in the replicate experiments are plotted on the x and y axes. B, same as panel A, except that cells 
were treated with or without 10 µM MG132 for 2 hours. C, Duplicate mass spectrometry 
experiments with label-free quantification were performed in which cells were either mock-
treated or supplemented with 10 µM NMS873 for 6 hours. Cells were treated with 800 µM DSP 
for 30 minutes prior to cell lysis, mixing of cell lysates, IP with anti-VCP, and mass 
spectrometry analysis. The ratios for each protein identified in the replicate experiments are 
plotted on the x and y axes. D, same as panel C, except that cells were treated with or without 10 
µM MG132 for 2 hours.  
 
Supplemental Fig. S7: Potential substrates for UFD1L–NPLOC4 and UBX domain 
proteins as determined by covariance analyses. 
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